Form 4: RA Capital Exchanges Fulcrum Therapeutics Shares for Prefunded Warrants

RA Capital Healthcare Fund exchanged 8,500,000 shares of Fulcrum Therapeutics common stock for an equal number of prefunded warrants.

Summary

• RA Capital Healthcare Fund, L.P. exchanged 8,500,000 shares of Fulcrum Therapeutics, Inc. common stock for 8,500,000 prefunded warrants.
• The warrants have an exercise price of $0.001 per share and no expiration date, being exercisable immediately.
• RA Capital Management, L.P. is the investment manager for the Fund.
• Peter Kolchinsky and Rajeev Shah, managing members of RA Capital Management GP, LLC, disclaim beneficial ownership except to the extent of their pecuniary interest.
• The Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The exchange provides Fulcrum with immediate capital, but the capped ownership for RA Capital introduces a limitation.

Positives

• The exchange provides Fulcrum Therapeutics with immediate capital, as the warrants are prefunded.

Risks

• The exercise of the warrants is capped at 9.99% ownership, which could limit RA Capital's potential upside.

Future Outlook

The document does not contain specific forward-looking statements beyond the terms of the warrant agreement.

Industry Context

This type of transaction, where shares are exchanged for prefunded warrants, is a common financing strategy in the biotech industry, allowing companies to raise capital while giving investors the potential for future equity upside.

Comparison to Industry Standards

• Similar transactions are often seen with other biotech companies seeking funding, such as XOMA Corporation's use of convertible notes and warrants.
• The 9.99% ownership limitation is a standard provision to avoid triggering certain regulatory thresholds and reporting requirements, similar to clauses found in financing agreements of companies like BioCryst Pharmaceuticals.

Stakeholder Impact

• Shareholders may see dilution upon exercise of the warrants.
• The company gains immediate access to capital.

Key Dates